

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Proposal for resolution to authorize the board of directors to issue ordinary shares and warrants to guarantors

In order to enable the issuing of units consisting of ordinary shares and warrants as compensation to those who have entered into guarantee commitments (the “**Guarantors**”) to secure the rights issue of units that was resolved upon by the board of directors on 23 July 2026, and which is proposed to be approved under item 8 on the agenda for the extraordinary general meeting, the board of directors of Alligator Bioscience AB, Reg. No. 556597-8201, proposes that the extraordinary general meeting on 26 August 2026 resolves to authorize the board of directors, for the period until the next annual general meeting, on one or several occasions, with deviation from the shareholders’ preferential rights and with or without provisions regarding set-off or other conditions, to resolve on issue of ordinary shares and warrants to the Guarantors.

Upon exercise of the authorization, the terms and conditions for units shall be the same as in the Rights Issue, meaning that each unit shall consist of two (2) ordinary shares, one (1) warrant series TO 15 and one (1) warrant series TO 16, including the subscription price in the Rights Issue.

The purpose of the authorization and the reason for the deviation from the shareholders’ preferential rights is to be able to carry out an issue of units as compensation to the Guarantors. The number of ordinary shares and warrants that may be issued pursuant to the authorization may not exceed the total number of ordinary shares and warrants corresponding to the agreed underwriting fee that the company has to pay to the Guarantors.

The resolution is conditional upon the meeting also resolving in accordance with items 6–8 and 10 in the notice.

For a valid resolution, the proposal must be supported by shareholders representing at least two-thirds of the votes cast as well as of all shares represented at the meeting.

The company’s CEO shall be authorized to make such minor formal adjustments of the resolution as might be necessary in connection with registration with the Swedish Companies Registration Office (Sw. Bolagsverket).

Lund in July 2026

The Board of Directors of Alligator Bioscience AB (publ)